Clinical Trial

AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to develop and validate a deep learning model to dynamically assess postoperative bleeding risk and assist in decision-making for re-operation in adult patients (≥18 years) diagnosed with primary gastric cancer undergoing radical gastrectomy. The main question\[s\] it aims to answer \[is/are\]: Can an AI model based on perioperative dynamic physiological parameters and precise intraoperative blood loss accurately predict the risk of postoperative bleeding requiring re-operation? Does the application of this AI model improve clinical decision-making (e.g., earlier warning time, optimal intervention timing) and patient outcomes (e.g., mortality, length of stay)? Since there is no comparison group (this is a pure observational study without intervention arms), researchers will not compare different treatment groups. Instead, the investigators will evaluate the model's performance (sensitivity, negative predictive value, AUC, calibration) using retrospective data for training and prospective multi-center data for external validation. Participants will: Undergo standard radical gastrectomy and routine postoperative care as per clinical practice (no study-specific interventions). Have their perioperative data collected, including demographics, medical history, vital signs, laboratory tests (blood gas analysis), surgical details, and precise intraoperative blood loss measurements. (For prospective participants only) Provide informed consent and complete follow-up assessments up to 30 days post-surgery.
Trial Details
NCT Number NCT07525765
Lead Sponsor First Affiliated Hospital of Zhejiang University
Collaborators: Jinhua Municipal Central Hospital, Second Affiliated Hospital of Nanchang University
Conditions Gastrectomy for Gastric Cancer, Gastric Cancer
Enrollment 7,000 participants
Start Date 2026-04-10
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13